Berinert on-demand treatment
"The sense of security for me
has been a relief."
Shari, Berinert Patient

Berinert is the only C1 esterase inhibitor (C1-INH) approved for on-demand treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and adolescents.

Recently Diagnosed Finding out that you or a loved one have been diagnosed with HAE can be emotional.

Living with HAE Find out how self-administered Berinert on-demand treatment fits into your HAE treatment plan.

Current Berinert Patients If you've already started treatment with Berinert, learn more about the support services Berinert provides.

Home
Expand

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human), is used in adults and children to treat swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat. The safety and efficacy of Berinert in preventing HAE attacks have not been established.

Do not use Berinert if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Inform your healthcare provider of all medications you are taking and of any medical conditions, especially any history of blood-clotting problems.

Blood clots have occurred in patients receiving Berinert. Tell your healthcare provider if you have a history of heart or blood vessel disease, stroke, or blood clots, or if you have thick blood, an indwelling catheter/access device in a vein, or have been immobile for some time. Certain medications, such as birth control pills, may also increase your risk of clotting problems.

Report to your physician or an emergency room any signs and symptoms of a blood clot, including pain and/or swelling or discoloration of an arm or leg, with warmth over affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In addition, report immediately any signs or symptoms of allergic reactions to Berinert, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

If you have been trained to self-administer Berinert, immediately prepare the prescribed dose at the first symptoms of an attack. Seek immediate medical attention and do not begin to self-adminster if an HAE attack has progressed to a point where you will be unable to prepare or administer a dose of Berinert.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Call your doctor right away if swelling is not controlled after use of Berinert.

In clinical studies, the most serious adverse reaction reported in subjects who received Berinert was an increased severity of the pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received Berinert than those receiving placebo was dysgeusia (a bad taste in mouth). Tell your healthcare provider about any side effect that bothers you or does not go away.

Because Berinert is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for Berinert, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Collapse
CSL Behring
© 2016 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059
Now Approved For Use In Pediatric Patients!
Help pediatric patients find fast, sustained relief
from HAE attacks with Berinert on demand.
1st and only HAE treatment indicated for use in children

Berinert is now approved for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema attacks in pediatric patients.

Important Safety Information
Dysgeusia was the most common adverse reaction reported in over 4% of subjects and more frequently than in the placebo group.

Please see Prescribing Information for Berinert, including the patient product information.